BioSpace News Archive

Mevion Medical Systems announced that it has signed a letter of intent to provide the MEVION S250i Proton Therapy System® with HYPERSCAN® Pencil Beam Scanning to an independent service provider in Texas.

Amneal Pharmaceuticals, Inc. announced its results for the first quarter ended March 31, 2020.

Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, announced positive topline results from its Phase III BRIDGE clinical trial of pegunigalsidase alfa, or PRX-102.

Cardinal Health reported financial results for the third quarter of fiscal 2020 ended March 31, 2020.Third quarter revenue was $39.2 billion, an increase of 11% from the third quarter of last year.

Eagle Pharmaceuticals, Inc. announced financial results for the three months ended March 31, 2020.

Codexis, Inc., a leading protein engineering company, announces that management will present at the UBS Virtual Healthcare Conference on Monday, May 18 at 9:10 a.m. Eastern time.

Worldwide Ocaliva net sales of $72.7 million in the first quarter 2020, representing 40% growth over the prior year quarter

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that management will participate in a fireside chat at the virtual BofA Securities 2020 Health Care Conference on May 14, 2020 at 1:40 p.m. ET.

Myriad Genetics, Inc. announced that the U.S. Food and Drug Administration approved the myChoice CDx® test for use as a companion diagnostic by healthcare professionals to identify advanced ovarian cancer patients with positive homologous recombination deficiency status, who are eligible or may become eligible, for first-line maintenance treatment with Lynparza in combination with bevacizumab.

Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced that Palmetto GBA, LLC, has announced the release date of June 21, 2020, for its final Local Coverage Decision policy covering Inspire therapy.